Novel therapeutics in multiple myeloma
Christoph Driessen et al.
Key factors in the tumor-tumor microenvironment relationship in myeloma
The importance of MRD negativity as a predictive marker in CLL
How can we treat elderly patients with AML?
Daratumumab in multiple myeloma: an overview of 3 key trials
Niels van de Donk